ReviewBiomedicines2022

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Tao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.